Psychiatry Research: Neuroimaging
Volume 173, Issue 3 , Pages 212-217 , 30 September 2009

Regional distribution and behavioral correlates of 5-HT2A receptors in Alzheimer's disease with [18F]deuteroaltanserin and PET

  • Lekshmi Santhosh

      Affiliations

    • Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, CT, USA
    • ,
  • Kristina M. Estok

      Affiliations

    • Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, CT, USA
    • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    • ,
  • Rebecca S. Vogel

      Affiliations

    • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    • Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA
    • ,
  • Gilles D. Tamagnan

      Affiliations

    • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    • Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA
    • ,
  • Ronald M. Baldwin

      Affiliations

    • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    • Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, CT, USA
    • Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA
    • ,
  • Effie M. Mitsis

      Affiliations

    • Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, CT, USA
    • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    • ,
  • Martha G. MacAvoy

      Affiliations

    • Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, CT, USA
    • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    • ,
  • Julie K. Staley

      Affiliations

    • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    • Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, CT, USA
    • Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA
    • Deceased.
    • ,
  • Christopher H. van Dyck

      Affiliations

    • Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, CT, USA
    • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
    • Department of Neurobiology, Yale University School of Medicine, New Haven, CT, USA
    • Corresponding Author InformationCorresponding author. Alzheimer's Disease Research Unit, Department of Psychiatry, Yale University School of Medicine, One Church Street, Suite 600, New Haven, CT 06510, USA. Tel.: +1 203 764 8100; fax: +1 203 764 8111.

Received 14 February 2008 ,Revised 2 December 2008 ,Accepted 16 March 2009.

References 

  1. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biological Psychiatry. 1988;23:271–284
  2. Biver F, Lotstra F, Monclus M, Wikler D, Damhaut P, Mendlewicz J, et al. Sex difference in 5HT2 receptor in the living human brain. Neuroscience Letters. 1996;204:25–28
  3. Blin J, Baron J, Dubois B, Crouzel C, Fiorelli M, Attar-Lèvy D, et al. Loss of brain 5-HT2 receptors in Alzheimer's disease. Brain. 1993;116:497–510
  4. Chen C-H, Alder J, Bowen D, Esiri M, McDonald B, Hope T, et al. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. Journal of Neurochemistry. 1996;66:1592–1598
  5. Cheng AVT, Ferrier IN, Morris CM, Jabeen S, Sahgal A, McKeith IG, et al. Cortical serotonin-S2 recptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. Journal of the Neurological Sciences. 1991;106:50–55
  6. Cross AJ. Serotonin in Alzheimer-type dementia and other dementing illness. Annals of the New York Academy of Sciences. 1990;600:405–417
  7. Cross A, Crow T, Ferrier I, Johnson J, Bloom S, Corsellis J. Serotonin receptor changes in dementia of the Alzheimer type. J. Neurochem. 1984;43:1574–1581
  8. Crouzel C, Guillaume M, Barre L, Lemaire C, Pike VW. Ligands and tracers for PET studies of the 5-HT system—current status. International Journal of Radiation Applications and Instrumentation, Part. B. 1992;19:857–870
  9. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308–2314
  10. Folstein MF, Fostein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12:189–198
  11. Halliday GM, McCann HL, Pamphlett R, Brooks WS, Creasey H, McCusker E, et al. Brain stem serotonin-synthesizing neurons in Alzheimer's disease: a clinicopathological correlation. Acta Neuropathologica. 1992;84:638–650
  12. Ichise M, Fujita M, Seibyl JP, Verhoeff NP, Baldwin RM, Zoghbi SS, et al. Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D2 receptor binding with [123I]epidepride SPECT. Journal of Nuclear Medicine. 1999;40:1902–1912
  13. Kirk RE. Experiment Design: Procedures for the Behavioral Sciences. Pacific Grove, CA.: Brooks/Cole Publishing Co.; 1982;
  14. Matsui T, Hirano A. An Atlas of the Human Brain for Computerized Tomography. Tokyo: Igaku-Shoin, Ltd; 1978;
  15. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939–944
  16. Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY, et al. Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology. 1998;18:407–430
  17. Meltzer CC, Smith G, Price JC, Reynolds CF, Mathis CA, Greer P, et al. Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. Brain Research. 1998;813:167–171
  18. Meltzer CC, Price JC, Mathis CA, Greer P, Cantwell MN, Houck PR, et al. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. American Journal of Psychiatry. 1999;156:1871–1878
  19. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports. 1962;10:799–812
  20. Palmer AM, Stratmann GC, Proctor AWP, Bowen DM. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Annals of Neurology. 1988;23:616–620
  21. Pike VW. Radioligands for PET studies of central 5-HT receptors and re-uptake sites—current status. Nuclear Medicine and Biology. 1995;22:1011–1018
  22. Procter AW, Francis PT, Stratmann GC, Bowen DM. Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms. Neurochemical Research. 1992;17:917–922
  23. Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Annals of Neurology. 1980;7:486–488
  24. Rosier A, Dupont P, Peuskens J, Bormans G, Vandenberghe R, Maes M, et al. Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging. Psychiatry Research Neuroimaging. 1996;68:11–22
  25. Soares JC, van Dyck CH, Tan P-Z, Zoghbi SS, Garg P, Soufer R, et al. Reproducibility of in vivo brain measures of 5-HT2A receptors with PET and [18F]deuteroaltanserin. Psychiatry Research Neuroimaging. 2001;106:81–93
  26. Staley JK, van Dyck CH, Tan P, Al-Tikriti M, Ramsby Q, Klump H, et al. Pharmacological characterization of [18F]deuteroaltanserin: a PET radiotracer for equilibrium imaging of serotonin-2A receptors. Nuclear Medicine and Biology. 2001;28:271–279
  27. Tampi RR, van Dyck CH. Behavioral and psychological symptoms of Alzheimer's disease. In:  Sun M-K editors. Research Progress in Alzheimer's Disease and Dementia. vol. 2:New York: Nova Science; 2007;p. 251–272
  28. Tan P-Z, Soares J, Baldwin RM, van Dyck CH, Soufer R, Seibyl JP, et al. H-2 and F-18 dual-labeled altanserin as a metabolically resistant PET ligand for serotonin-2A (5-HT2A) receptor. Journal of Nuclear Medicine. 1998;39:21P
  29. Tan P-Z, Baldwin RM, Fu T, Charney DS, Innis RB. Rapid synthesis of F-18 and H-2 dual-labeled altanserin, a metabolically resistant PET ligand for 5-HT2A receptors. Journal of Labelled Compounds & Radiopharmaceuticals. 1999;42:457–467
  30. Tan P-Z, Baldwin RM, van Dyck CH, Al-Tikriti M, Amici L, Roth B, et al. Characterization of the radioactive metabolites of the 5-HT2A receptor ligand [18F]altanserin in human, baboon, and rodent. Nuclear Medicine and Biology. 1999;26:601–608
  31. van Dyck CH, Soares J, Tan P-Z, Staley JK, Baldwin RM, Amici LA, et al. Equilibrium modeling of 5-HT2A receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigm. Nuclear Medicine and Biology. 2000;27:715–722
  32. van Dyck CH, Tan P-Z, Baldwin RM, Amici LA, Garg PK, Ng CK, et al. PET quantification of 5-HT2A receptors in the human brain: a constant infusion paradigm with [F-18]altanserin. Journal of Nuclear Medicine. 2000;41:234–241
  33. Versijpt J, Van Laere KJ, Dumont F, Decoo D, Vandecapelle M, Santens P, et al. Imaging of the 5-HT2A system: age-, gender-, and Alzheimer's disease-related findings. Neurobiology of Aging. 2003;24:553–561
  34. Watson CC. New, faster, image-based scatter correction for 3D PET. IEEE Transactions on Nuclear Science. 2000;47:1587–1594
  35. Whitehouse PJ. Neurotransmitter receptor alterations in Alzheimer's disease: a review. Alzheimer Disease and Associated Disorders. 1987;1:9–18
  36. Xu M, Luk WK, Cutler PD, Digby WM. Local threshold for segmented attenuation correction of PET imaging of the thorax. IEEE Transactions on Nuclear Science. 1994;41:1532–1537
  37. Xu M, Cutler PD, Luk WK. Adaptive segmented attenuation correction for whole-body PET imaging. IEEE Transactions on Nuclear Science. 1996;43:331–336
  38. Zubenko GS, Moossy J, Kopp U. Neuropathologic correlates of major depression in primary dementia. Archives of Neurology. 1990;47:209–214
  39. Zubenko GS, Moossy J, Martinez A, Rao G, Classen D, Rosen J, et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Archives of Neurology. 1991;48:619–624
  40. Zweig RM, Ross CA, Hedreen JC, Steele C, Cardillo JE, Whitehouse PJ, et al. The neuropathology of aminergic nuclei in Alzheimer's disease. Annals of Neurology. 1988;24:233–242

PII: S0925-4927(09)00083-3

doi: 10.1016/j.pscychresns.2009.03.007

Psychiatry Research: Neuroimaging
Volume 173, Issue 3 , Pages 212-217 , 30 September 2009

Article Tools

* Image Usage & Resolution